SPOTLIGHT: Novartis, Teva eye Aurobindo


India's Aurobindo Pharma is reportedly in talks with Novartis and Teva over the sale of a strategic investment in the antibiotics manufacturer. No one at any of the companies was talking, but Aurobindo's role in supplying low-cost generics to developing countries offers a tempting target for global pharma companies like Novartis and Teva. Report

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.